About Gregory Stock
Dr. Gregory Stock is a leading authority on the broad impacts of genomic and other advanced technologies in the life sciences. He was the co-founder and CEO both of Signum Biosciences, a Princeton-based biotechnology company developing therapeutics for Alzheimer’s and other neurodegenerative diseases, and of Ecoeos, an innovative genomics company offering genetic tests for susceptibility to environmental toxins.
Dr. Stock explores our sense of the human using diverse questions about what it would mean to alter fundamental aspects of our biology, build conscious beings out of silicon, and continue our rapid technological advance.
A biophysicist by training, he approaches these and other big issues in pragmatic, down-to-earth ways that challenge our thinking and values.
He is a major game changer and thought leader who tackles controversial issues.